Phytobacterium plantarum KSFY05 and application thereof in preparation of medicine for treating depression

By using the KSFY05 planta lactobacterium KSFY05 isolated from traditional fermented yogurt in Kashgar, Xinjiang, the depression symptoms of CUMS mice were significantly improved, and the deficiency of microbial mediated treatment of depression in the prior art was solved, and effective probiotics for depression were provided. Screening of candidate strains achieved significant improvements in anxiety, depression and despair behavior.

CN118909855AInactive Publication Date: 2024-11-08CHONGQING UNIV OF EDUCATION
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411059202.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-03
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat depression, especially through microbial-mediated methods, and there is a lack of effective probiotic screening candidate strains for anxiety and depression.

Method used

By constructing a CUMS depression mouse model, Lactiplantibacillus plantarum KSFY05 (Lactiplantibacillus plantarum KSFY05) from traditional fermented yogurt in Kashgar, Xinjiang was used to evaluate its effect on reducing anxiety, depression and despair behaviors, and to explore its preparation and treatment of depression Application of drugs in symptom. This strain significantly increased the 5-HT concentration in mice through gavage intervention, reduced ACTH and IL-6 concentrations, and upregulated mTORC1, PGC-1α, SIRT1, TPH1 and TPH2 mRNA expression levels, improving monoamine neurotransmitter disorders and Neuroprotection.

Benefits of technology

P. plantarum KSFY05 significantly alleviates anxiety, depression and despair behavior in mice, increases 5-HT concentration, reduces inflammatory markers, and its high-concentration intervention effect is close to the positive drug fluoxetine, providing science to alleviate depression and anxiety. in accordance with.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909855A_ABST
    Figure CN118909855A_ABST
Patent Text Reader

Abstract

The invention provides a plant lactobacillus KSFY05 and application thereof in preparation of a medicine for treating depression, and relates to the technical field of microorganisms. The plant lactobacillus KSFY05 disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.15658. According to the invention, a CUMS depression mouse model is constructed, and the effect and the specific mechanism of the plant lactobacillus KSFY05 separated from the traditional fermented yoghurt in the karst region of Xinjiang for improving the depression-like behavior of the CUMS mouse are evaluated according to the weight change condition of the mouse, behavioral analysis (open field experiment and tail suspension experiment) and the change of depression-related biomarkers in the prefrontal cortex; candidate strains are screened for developing probiotic functional foods for relieving depression and anxiety, and a scientific basis is provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention provides a lactobacillus plantarum KSFY05 and application thereof in preparing a medicine for treating depression, belonging to the technical field of microorganisms. Background Art

[0002] Depression is a common, comprehensive mental disorder caused by multiple factors. The World Health Organization has listed depression as the leading single factor in global disability or non-fatal health loss. At the same time, depression is also one of the main factors causing global disease burden and suicide. Therefore, preventing, alleviating and treating depression is an urgent global public issue.

[0003] In recent years, the intestinal microbiome is believed to be closely related to the function of the central nervous system and psychopathological diseases, which has attracted the attention of the scientific community to the potential of probiotics in treating depression, and the "psycho-probiotic" therapy has also been proposed. In order to explore the potential benefits of probiotics for anxiety and depression, scientists have conducted a number of studies in cell and animal models, preliminarily revealing the intervention effects and potential mechanisms of probiotics on depression, such as increasing the production of γ-aminobutyric acid, 5-HT or other neurotransmitters, regulating the HPA axis and reducing inflammatory markers. Among them, Lactobacillus paracasei PS23 can normalize the levels of 5-HT and dopamine in the hippocampus, help reduce anxiety, depression and age-related cognitive decline, and Lactobacillus plantarum 286 showed anti-depressant and anti-anxiety effects after continuous administration for 30 days in Swiss male mice. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a plant lactobacillus KSFY05 and its application in the preparation of a drug for treating depression. The present invention constructs a CUMS depression mouse model, selects fluoxetine as a positive drug control, evaluates the effect and specific mechanism of plant lactobacillus KSFY05 isolated from traditional fermented yogurt in Kashgar, Xinjiang on improving the depressive-like behavior of CUMS mice from the changes in mouse weight, behavioral analysis (open field test and tail suspension test) and changes in depression-related biomarkers in the prefrontal cortex, and screens candidate strains for the development of probiotic functional foods that relieve depression and anxiety, and provides a scientific basis.

[0005] The plant lactobacillus KSFY05 (LP-KSFY05) of the present invention is separated from naturally fermented yak yogurt in Kashgar, Xinjiang by the Collaborative Innovation Center for Children's Nutrition and Healthy Development, and is currently preserved in the China General Microbiological Culture Collection Center with a preservation number of CGMCCNO.15658.

[0006] The present invention experimentally verified that the concentration of 1.0×109 CFU / kg LP-KSFY05 gavage intervention can significantly reduce the anxiety, depression and despair behaviors of mice in the open field test and tail suspension test in behavioral tests; significantly increase the 5-HT concentration in the prefrontal cortex, reduce the ACTH and IL-6 concentrations; and significantly upregulate the relative expression levels of mTORC1, PGC-1α, SIRT1, TPH1 and TPH2 mRNA. In summary, Lactobacillus plantarum LP-KSFY05 can improve the symptoms of monoamine neurotransmitter disorders in CUMS mice by increasing the 5-HT content and the relative expression of TPH1 and TPH2 mRNA, activating mTORC1 to stimulate mTOR synaptogenesis, and slowing down the development of depression by upregulating PGC-1α and SIRT1 mRNA levels to achieve neuroprotection and neurogenesis. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 The effect of LP-KSFY05 on the body weight changes of mice;

[0008] Figure 2 The effect of LP-KSFY05 on open field behavior of mice;

[0009] Figure 3 The effect of LP-KSFY05 on the tail suspension behavior of mice;

[0010] Figure 4 The effect of LP-KSFY05 on the concentrations of 5-HT, ACTH, and IL-6 in the prefrontal cortex of mice;

[0011] Figure 5 This is the effect of LP-KSFY05 on the relative expression levels of mTORC1, PGC-1α, SIRT1, TPH1 and TPH2 mRNA in the cerebral cortex of mice. DETAILED DESCRIPTION

[0012] In order to make the purpose, technical scheme and advantages of the present invention clearer, the preferred embodiments of the present invention are further described in detail in conjunction with the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0013] 1 Materials and reagents

[0014] Experimental strain: Lactiplantibacillus plantarum KSFY05 (LP-KSFY05) was isolated from naturally fermented yak yogurt in Kashgar, Xinjiang by the Collaborative Innovation Center for Children's Nutrition and Healthy Development. It is now preserved in the China General Microbiological Culture Collection Center with the collection number CGMCCNO.15658.

[0015] Table 1 Experimental materials and reagents

[0016]

[0017]

[0018] 2. Instruments and Equipment

[0019] Table 2 Instruments and equipment

[0020]

[0021]

[0022] 3 Experimental methods

[0023] 3.1 Animal Experiment Design

[0024] Fifty 6-week-old (20±1g) SPF-grade male C57BL / 6 mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. [Animal Qualification License No.: SCXK (Xiang) 2019–0004] and kept in a constant temperature and humidity environment with a temperature of 25±2℃ and a humidity of 50±5%. The mice were fed and drunk freely every 12 hours. All animal experiments were carried out in strict accordance with the laboratory animal use regulations and animal ethics experimental requirements. After 7 days of adaptive feeding, the mice were randomly divided into 5 groups, namely: normal group, fluoxetine group, positive control group, LP-KSFY05 low concentration group and LP-KSFY05 high concentration group. Except for the normal group, all mice in other groups were subjected to chronic unpredictable mild stimulation for 5 weeks, and the mice were gavaged or intraperitoneally injected every day. The normal group and the fluoxetine group were gavaged with 0.2 mL of sterile saline every day, the fluoxetine group was intraperitoneally injected with 10 mg / kg fluoxetine, and the low and high concentration LP-KSFY05 groups were gavaged with 1×10 7 CFU / kg and 1×10 9 CFU / kg of LP-KSFY05 live bacterial suspension. A one-week behavioral test began in the sixth week.

[0025] 3.2 CUMS modeling method

[0026] After one week of adaptive feeding of mice, the CUMS depression model was constructed to simulate various stress stimuli in human life. During the modeling process, the mice in the blank control group were not given any stimulation and ate and drank water normally. The model group, fluoxetine group, LP-KSFY05 low concentration group and LP-KSFY05 high concentration group were given a random mild chronic stress stimulus once a day, and the same stimulus was not applied for three consecutive days. Each stress condition appeared randomly to avoid animal foresight. The specific CUMS implementation method is as follows:

[0027] (1) Tilted cage: Raise one end of the cage and tilt it 45° for 24 hours;

[0028] (2) Fasting: remove the mouse food for 24 h;

[0029] (3) Water deprivation + empty bottle stimulation: pour out the water in the water bottle and place the empty bottle in its original position for 24 hours;

[0030] (4) No bedding: remove the bedding from the cage for 8 h;

[0031] (5) Continuous illumination: The mice were exposed to continuous illumination for 24 h;

[0032] (6) Crowding stimulation: placing partitions in the mouse cage to reduce the activity area of ​​the mice for 24 hours;

[0033] (7) Tail clamp: clamp the tail 1 cm away from the tip with hemostatic forceps for 60 seconds;

[0034] (8) Reversing the day and night cycle: Reversing the day and night cycle, the mouse cage was covered with a black cloth during the day, the black cloth was removed at 19:30, and the lights were turned on to simulate a bright light environment until 19:30 the next day;

[0035] (9) Restraint: mice were confined in a 50 mL plastic syringe for 2 h;

[0036] (10) Wet bedding: Sprinkle 200 mL of water into the bedding for 8 h.

[0037] The success of the modeling was analyzed and judged based on the results of subsequent behavioral experiments.

[0038] 3.3 Behavioral test - open field test

[0039] The open field test is used to evaluate the autonomous behavior, exploratory activities and tension of experimental animals in a novel environment. The mice were placed in the center of the open field device, and the time was immediately started and the whole process was recorded. The observation time was 6 minutes. After each experiment, the surroundings and the bottom should be wiped with alcohol to avoid residual animal information affecting the results. The video was digitally analyzed using AYN-mase 7.0 software to record the movement distance of the mice in the open field, the number of times the middle grid was crossed, and the time they stayed in the central area.

[0040] 3.4 Behavioral test - tail suspension test

[0041] The tail suspension test is used to evaluate the despair behavior of mice. The mouse's tail is fixed with tape at the back 1 / 3 and suspended 40 cm above the ground. The mouse is 15 cm away from the nearest object and is isolated from hearing and vision. Video recording software is used to record the video in time and stop recording after 6 minutes of observation. The software is used to analyze the immobility time of 3-6 minutes after tail suspension. The timing starts when the animal gives up active struggle and is completely immobile.

[0042] 3.5 Mouse dissection and sampling

[0043] After all behavioral tests were completed, the mice were fasted but not watered for 12 hours, and then all mice were euthanized and biological samples were collected. The hippocampus and prefrontal cortex were carefully dissected out on ice, placed in sterile centrifuge tubes, and stored at -80°C for later use.

[0044] 3.6 Determination of 5-HT, ACTH and IL-6 in the prefrontal cortex of mice

[0045] According to the instructions of the enzyme linked immunosorbent assay (ELISA) kit, the concentrations of 5-HT, ACTH and IL-6 in the mouse prefrontal cortex were measured.

[0046] 3.7 Determination of mTORC1, PGC-1α, SIRT1, TPH1, and TPH2 mRNA expression levels in mouse hippocampus and prefrontal cortex

[0047] Weigh an appropriate amount of mouse hippocampus or prefrontal cortex tissue, add TRIzol for homogenization to extract RNA from mouse ileum tissue, and then use a spectrophotometer to measure the concentration and purity of the RNA extract, and reverse transcribe the RNA extract into cDNA according to the instructions of the reverse transcription kit. After reverse transcription, prepare the cDNA reaction system in an eight-tube strip, namely 10μL of Master mix, 1μL of upstream and downstream primers, 1μL of template cDNA, and 7μL of sterile enzyme-free water. The prepared reaction system is amplified and detected using real-time fluorescence quantitative PCR (Quantitative Real-time PCR, qPCR) technology. Amplification conditions: pre-denaturation at 95℃ for 5min, then denaturation at 95℃ for 10s, annealing at 60℃ for 30s, and the whole process is repeated 40 times. After the determination, HprT is used as the internal reference gene and the formula 2 is used. -ΔΔCT Determine the relative expression of the target gene. The primer sequences used in this experiment are shown in Table 3.

[0048] Table 3 Primer sequences

[0049]

[0050]

[0051] 3.8 Data processing and statistical analysis

[0052] All data were expressed as mean ± standard deviation (SD) and analyzed using IBM SPSS 23.0 statistical software. One-way analysis of variance (ANOVA) and Duncan's multiple range test were used for comparison between groups. The same lowercase letters in ae indicate no significant difference between the two groups, and different lowercase letters indicate significant difference between the two groups (P < 0.05).

[0053] 4 Results and analysis

[0054] Effect of LP-KSFY05 on the body weight of CUMS mice

[0055] The induction of CUMS can cause weight loss in mice. Figure 1 As shown in the figure, after the first week of adaptation, there was no significant difference in the weight of mice in each group, and the weight growth trend was basically the same. Two weeks after induction, compared with the normal group, the weight growth rate of mice in the model group, fluoxetine group, LP-KSFY05 low concentration group and LP-KSFY05 high concentration group decreased, and the weight of each group began to show significant differences. From the third week, the weight of mice in the model group decreased significantly (P<0.05). At the end of the experimental modeling in the sixth week, the weight of mice in the model group was the lightest, and the other four groups had significant differences (P<0.05). Among them, the weight of the LP-KSFY05 high concentration group was significantly heavier than that of the LP-KSFY05 low concentration group (P<0.05), and there was no significant difference between it and the fluoxetine group (P>0.05). The results showed that the weight gain rate of mice decreased after CUMS induction, while after intervention with fluoxetine and LP-KSFY05, the weight gain rate of mice increased. The high-concentration LP-KSFY05 group showed an effective effect in maintaining the normal weight of mice, which was better than the low-concentration LP-KSFY05 group (P<0.05) and similar to the fluoxetine group (P>0.05). This shows that Lactobacillus plantarum KSFY05 intervention in the experiment can significantly improve the weight loss of mice caused by CUMS, but there is still a certain gap from the weight gain state of normal mice.

[0056] 4.2 Effects of LP-KSFY05 on the behavior of CUMS mice

[0057] The anxiety and depression-like behaviors of mice were evaluated by open field test and tail suspension test. In the open field test, the time spent in the center area and the frequency of entering the center area are indicators of anxiety and depression behaviors of mice. Figure 2A in the middle is the result of the open field experiment; B is the heat map of the open field action trajectory. Figure 2 Different lowercase letters indicate significant differences (P﹤0.05). Figure 2 As shown in A, compared with the normal group, the model group mice that were induced by CUMS without any intervention treatment had the shortest total crawling distance in the open field, the least number of crossings in the middle grid, and the lowest percentage of time spent in the middle grid. The experimental results of the mice in the fluoxetine group, the low-concentration LP-KSFY05 group, and the high-concentration LP-KSFY05 group were significantly higher than those in the model group, and there were significant differences between the groups (P<0.05). The overall trend showed that the fluoxetine group was better than the high-concentration LP-KSFY05 group, and the high-concentration LP-KSFY05 group was better than the low-concentration LP-KSFY05 group. It is worth mentioning that high-concentration LP-KSFY05 can significantly increase the total crawling distance of CUMS mice in the open field, and its effect is not significantly different from that of the fluoxetine group (P>0.05). Figure 2 B is a heat map of behavioral trajectories in the open field experiment, which intuitively shows the movement trajectories of the experimental mice in the mine field within 6 minutes. The results showed that CUMS induced a significant decrease in the activity of mice, which was significantly improved after intervention with fluoxetine and KSFY05, and the activity of mice returned to normal, and the regulatory effect of high concentration of KSFY05 was significantly better than that of low concentration (P<0.05).

[0058] The tail suspension test reflects the desperate behavior of animals by analyzing the duration of the animal's struggle for survival and the duration of desperate immobility after the animal's body is inverted. Figure 3 As shown in the figure, compared with the normal group, the immobility time of the model group mice was significantly increased, indicating that the model group mice had strong despair and gave up struggling. After intervention with fluoxetine and LP-KSFY05, the immobility time, number of immobility and percentage of immobility time of mice were significantly reduced (P<0.05), especially in the high-concentration LP-KSFY05 group, the immobility time of mice was not significantly different from that of the fluoxetine group (P>0.05). At the same time, the trends of the number of immobility times and percentage of immobility time of tail suspension of mice were consistent with the immobility time of tail suspension of mice. It shows that the intervention of LP-KSFY05 can effectively alleviate the despair of CUMS mice.

[0059] Effects of LP-KSFY05 on 5-HT, ACTH and IL-6 levels in the prefrontal cortex of CUMS mice

[0060] As a neurotransmitter, 5-HT can guide the brain to produce pleasant emotions. The decrease in its concentration in brain tissue is directly related to psychological and emotional changes, thereby inducing the occurrence of depression. Figure 4As shown in A, compared with the normal group, the 5-HT content in the prefrontal cortex of the model group mice affected by CUMS was significantly reduced (P<0.05). After intervention with fluoxetine and LP-KSFY05, the 5-HT concentration in the prefrontal cortex of mice was significantly increased on the basis of the model group (P<0.05), among which the LP-KSFY05 high concentration group was significantly higher than the LP-KSFY05 low concentration group (P<0.05), and there was no significant difference in the 5-HT content in the prefrontal cortex of mice treated with fluoxetine (P>0.05). At the same time, CUMS can cause a significant increase in the ACTH content in the prefrontal cortex of mice ( Figure 4 B), while the intervention of fluoxetine and LP-KSFY05 can significantly reduce the increase of ACTH caused by CUMS, among which the high-concentration LP-KSFY05 group has better effect than the low-concentration LP-KSFY05 group (P<0.05). In addition, IL-6 is a key pro-inflammatory cytokine and plays an important role in the regulation of inflammation and immunity. Figure 4 C shows that compared with the normal group, the IL-6 level in the prefrontal cortex of mice in the model group was the highest, indicating that CUMS can lead to an increase in the content of proinflammatory cytokines in mice. After intervention with fluoxetine and LP-KSFY05, the IL-6 concentration in the prefrontal cortex of mice was significantly reduced (P<0.05), indicating that fluoxetine and LP-KSFY05 both have a good effect in alleviating inflammation in mice, among which high concentration of LP-KSFY05 has a better effect than low concentration.

[0061] Effect of LP-KSFY05 on the relative expression of mTORC1, PGC-1α, SIRT1, TPH1 and TPH2 mRNA in the prefrontal cortex of CUMS mice

[0062] like Figure 5 As shown in the data, compared with the normal group, CUMS caused a significant downregulation in the relative mRNA expression of mTORC1, PGC-1α, SIRT1, TPH1 and TPH2 in the prefrontal cortex of the mouse brain (P<0.05), while after intervention with fluoxetine and LP-KSFY05, their expression levels showed a significant upward trend (P<0.05), among which the intervention with the drug fluoxetine showed the best effect, and the effect of high concentration of LP-KSFY05 was significantly better than that of low concentration of LP-KSFY05 (P<0.05).

[0063] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

Claims

1. A Lactobacillus plantarum KSFY05, characterized in that The Lactobacillus plantarum KSFY05 is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with the deposit number being CGMCC No.15658.

2. Use of Lactobacillus plantarum KSFY05 as claimed in claim 1 in preparing a drug for treating depression.

Citation Information

Cited By

  • High-activity plant lactobacillus KL100 for relieving anxiety and depression and application of high-activity plant lactobacillus KL100

    CN120041355A

  • Lactobacillus plantarum for regulating mood health and resisting depression and application of lactobacillus plantarum

    CN120137860A